Organon & Co. (OGN)
OGN moved a median of +0.06% 30 minutes after news, and -0.13% by the close. How OGN actually reacts to news — the realized, point-in-time move the market made, measured across 1,185 labeled events over the last three years with zero look-ahead.
OGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 1,179 |
| 30-min | +0.06% | 51% | 1,179 |
| 60-min | +0.10% | 56% | 1,179 |
| to close | -0.13% | 46% | 1,181 |
| Middle 50% of OGN reactions | -0.64% to +0.74% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 1,185 |
Half of all Organon & Co. news events land between -0.64% and +0.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.14% | 55% | +0.33% |
| Analyst downgrades | 16 | -1.00% | 19% | -0.16% |
| Rating reiterations | 16 | +0.19% | 75% | +0.04% |
| Price-target cuts | 11 | -0.12% | 46% | -0.79% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how OGN ranks against every other measured name →
That’s how OGN usually reacts — get an email when it moves on news →Email me when OGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OGN's baseline. Nothing else.
Recent OGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing | Press release | Business Wire | -0.07% | -0.14% | |
| Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting | Press release | Business Wire | +0.00% | -0.07% | |
| Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference | Press release | Business Wire | +0.04% | +0.00% | |
| Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older | Press release | Canada Newswire | +0.13% | +0.07% | |
| Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device | Press release | Business Wire | +0.07% | +0.07% | |
| National Can-RISE Study to Help Close Critical Gaps in Menopause Research | Press release | GlobeNewswire | +0.04% | +0.00% | |
| Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability | Press release | Business Wire | +0.07% | +0.29% | |
| Organon Announces Quarterly Dividend | Press release | Business Wire | -0.04% | +0.00% | |
| New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults¹ | Press release | Business Wire | -0.15% | -0.44% | |
| ORGANON CANADA ANNOUNCES THE APPOINTMENT OF DOMINIC BÉGIN AS PRESIDENT AND MANAGING DIRECTOR | Press release | Canada Newswire | +0.00% | +0.00% | |
| Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing | Press release | Business Wire | +0.07% | +0.00% | |
| Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting | Press release | Business Wire | +0.04% | -0.29% | |
| Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA | Press release | Business Wire | +0.00% | +0.37% | |
| Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device | Press release | Business Wire | +0.07% | -0.15% | |
| Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada | Press release | Business Wire | -0.07% | -0.07% | |
| Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 | Press release | Business Wire | +0.11% | -0.07% | |
| Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | +0.11% | -0.07% | |
| Organon to Present New Research on Access and Value at ISPOR 2026 | Press release | Business Wire | -0.15% | +0.22% | |
| Organon Reports Results for the First Quarter Ended March 31, 2026 | Press release | Business Wire | +0.22% | -0.53% | |
| European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe | Press release | PR Newswire | +0.00% | +0.00% | |
| European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe | Press release | Business Wire | +0.00% | +0.00% | |
| Organon Cancels First Quarter Earnings Call | Press release | Business Wire | +0.00% | +0.00% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO) | Press release | GlobeNewswire | +0.00% | -0.15% | |
| Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | -0.04% | +0.91% | |
| OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.08% | -0.15% | |
| Sun Pharma signs Definitive Agreement to Acquire Organon | Press release | Business Wire | -0.08% | -0.15% | |
| Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 | Press release | Business Wire | -2.74% | -3.52% | |
| Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis | Press release | Business Wire | -0.40% | +5.62% | |
| Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants | Press release | PR Newswire | +0.00% | -3.72% | |
| Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age | Press release | Business Wire | -0.08% | -4.26% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.08% | -0.31% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.37% | +0.46% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.22% | -0.22% | |
| Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.99% | +1.84% | |
| New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis | Press release | Business Wire | +0.00% | +1.11% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.25% | +0.43% | |
| Form 10-K Organon & Co. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.62% | -7.40% | |
| Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device | Press release | Business Wire | -0.87% | -1.86% | |
| Form 8-K Organon & Co. For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | +5.33% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.07% | -0.27% | |
| Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.45% | -0.55% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.47% | -1.89% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.22% | +3.07% | |
| Form 8-K Organon & Co. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | +5.53% | |
| Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 | Press release | Business Wire | -0.15% | +5.53% | |
| Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 | Press release | Business Wire | -0.11% | -3.15% | |
| Organon Completes Divestiture of JADA® System to Laborie | Press release | Business Wire | -0.22% | -1.93% | |
| Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque | Press release | Business Wire | +2.71% | +4.53% | |
| Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway | Press release | Business Wire | -0.25% | +0.49% | |
| Organon To Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | Business Wire | +1.46% | +4.74% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OGN section they belong to.
Where else OGN is measured.
OGN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Organon & Co.'s median reaction calculated?
Every labeled OGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,185 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of OGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.